Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo Predicts Upturn On OTC Private Label Breadth, Depth And Bandwidth

Executive Summary

Perrigo counts on its OTC private label dominance to thwart new store brand entries and give it a leg-up in e-commerce sales, which are growing at 50% year-to-year. Private label is "a distinctly different business than the national brand space," says consumer health executive Jeffrey Needham.

You may also be interested in...



Perrigo CEO Takes Faith In Rx Generics Business To Exit Door With Him

Private label OTC business is likely to be strengthened as Perrigo’s core, as CEO Hendrickson announces retirement shortly after hedge fund investor Starboard Value, pushing to divest the Rx business, built a five-seat block on Perrigo's board.

Perrigo OTC Growth Rides Innovation Path Wider Than Switches

When Perrigo executives confirmed their faith during an earnings briefing in the firm's OTC private label as its primary revenue driver, some analysts wanted more as assurance that the business will continue stabilizing the firm.

Navigating Amazon: E-Commerce Giant Critical For OTC Drug Sales

As Amazon emerges as the leading search engine for information about consumer packaged goods products, OTC drug and other consumer health product firms should establish a presence, even if they expect not to sell much, says BeeKeeper consultancy's Lynn Graham.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS120934

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel